Long-term maintenance of pediatric asthma: Focus on budesonide/formoterol inhalation aerosol

Therapeutics and Clinical Risk Management

Volumn 6, Issue 1, 2010, Pages 65-75

  Huynh, Peter N ^a   Scott, Lyne G ^a   Kwong, Kenny Y C ^b  

^a LAC USC MEDICAL CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Asthma; Budesonide; Children; Control; Formoterol; Long term

Indexed keywords

ANTIHISTAMINIC AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL; PLACEBO; PREDNISONE; PROTON PUMP INHIBITOR; SALBUTAMOL; STEROID; TERBUTALINE;

ADRENAL SUPPRESSION; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BONE DENSITY; BRONCHODILATATION; CATARACT; CHEST TIGHTNESS; CLINICAL TRIAL; COMORBIDITY; COUGHING; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; DYSPNEA; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GENOTYPE; GLAUCOMA; GROWTH RATE; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; OROPHARYNX CANDIDIASIS; PATIENT ATTITUDE; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SINUSITIS; SKIN BRUISING; UPPER RESPIRATORY TRACT INFECTION; WHEEZING;

EID: 77950840709     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 3. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute; 2007.
2. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. Global Initiative for Asthma (GINA) program: the global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469-478.
3. Siersted HC, Boldsen J, Hansen HS, Mostgaard G, Hyldebrandt N. Population based study of risk factors for underdiagnosis of asthma in adolescence: Odense schoolchild study. BMJ. 1998;316(7132): 651-655; discussion, 655-656.
4. Speight AN, Lee DA, Hey EN. Underdiagnosis and undertreatment of asthma in childhood. Br Med J (Clin Res Ed). 1983;286(6373): 1253-1256.
5. Nichols B, Scott L, Jones S, Kwong KY, Morphew T, Jones CA. Detection of undiagnosed and poorly controlled asthma in a hospital-based outpatient pediatric primary care clinic using a health risk assessment system. J Asthma. 2009;46(5):498-505.
6. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152(3):1107-1136.
7. American Thoracic Society and European Respiratory Task Force. Standardization of lung function testing. Eur Respir J. 2005;26:948-968.
8. Tager IB, Hanrahan JP, Tosteson TD, et al. Lung function, pre- and post-natal smoke exposure, and wheezing in the first year of life. Am Rev Respir Dis. 1993;147(4):811-817.
9. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophillic inflammation. J Allergy Clin Immunol. 2004;113(1):101-108.
10. Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med. 2004;10(1):44-50.
11. Kelley CF, Mannino DM, Homa DM, Savage-Brown A, Holguin F. Asthma phenotypes, risk factors, and measures of severity in a national sample of US children. Pediatrics. 2005;115(3):726-731.
12. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000;162(4 Pt 1): 1403-1406.
13. Bateman ED, Boushey HA, Bousquet J, et al; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836-844.
14. Kwong KY, Morphew T, Scott L, Guterman J, Jones CA. Asthma control and future asthma-related morbidity in inner-city asthmatic children. Ann Allergy Asthma Immunol. 2008;101(2):144-152.
15. Scott L, Nichols B, Choi Kwong KY, Morphew T, Jones CA. Longitudinal patterns of predominant asthma disease activity in pediatric patients enrolled in an asthma-specific disease management program. J Asthma. 2008;45(6):501-505.
16. Calhoun WJ, Sutton LB, Emmett A, Dorinsky PM. Asthma variability in patients previously treated with beta2-agonists alone. J Allergy Clin Immunol. 2003;112(6):1088-1094.
17. Sears MR. Epidemiology of asthma exacerbations. J Allergy Clin Immunol. 2008;122(4):662-668.
18. Tan WC. Viruses in asthma exacerbations. Curr Opin Pulm Med. 2005;11(1):21-26.
19. Jones CA, Clement LT, Morphew T, et al. Achieving and maintaining asthma control in an urban pediatric disease management program: the Breathmobile Program. J Allergy Clin Immunol. 2007;119(6):1445-1453.
20. Howell G. Nonadherence to medical therapy in asthma: risk factors, barriers, and strategies for improving. J Asthma. 2008;45(9):723-729.
21. Haughney J, Price D, Kaplan A, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med. 2008;102(12):1681-1693.
22. Burgess SW, Sly PD, Morawska A, Devadason SG. Assessing adherence and factors associated with adherence in young children with asthma. Respirology. 2008;13(4):559-563.
23. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol. 2001;107(3):469-476.
24. Braunstahl GJ, Hellings PW. Nasobronchial interaction mechanisms in allergic airway airways disease. Curr Opin Otolaryngol Head Neck Surg. 2006;14(3):176-182.
25. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol. 2002;109(4):636-642.
26. Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol. 2004;113(3):415-419.
27. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma; the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol. 2002;109(1):57-62.
28. Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Gastroesophageal reflux in asthmatics; a double-blind, placebo-controlled crossover study with omeprazole. Chest. 1999;116(5):1257-1264.
29. Littner MR, Leung FW, Ballard ED 2nd, Huang B, Samra NK; Lansoprazole Asthma Study Group. Effects of 24 weeks of lansoprazole therapy on asthma symptoms exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest. 2005;128(3):1128-1135.
30. Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med. 1995;152(1):45-52.
31. Busse WW. What role for inhaled steroids in chronic asthma? Chest. 1993;104(5):1565-1571.
32. Duddridge M, Ward C, Hendrick DJ, Walters EH. Changes in bron-choalveolar lavage inflammatory cells in asthmatic patients treated with high dose inhaled beclomethasone dipropionate. Eur Respir J. 1993;6(4):489-497.
33. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyper-responsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990;142(4):832-836.
34. Barnes PJ, Pederson S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis. 1993;148(4 Pt 2):S1-S26.
35. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332-336.
36. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ. 1990;300(6739):1548-1551.
37. Brown PH, Greening AP, Crompton, et al. Large volume spacer devices and the influence of high dose beclomethasone dipro-pionate on hypothalamo-pituitary-adrenal axis function. Thorax. 1993;48(3):233-238.
38. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941-955.
39. Pauwels RA, Yernault JC, Demedts MG, Geusens P. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. Am J Respir Crit Care Med. 1998;157(3 Pt 1):827-832.
40. Roux C, Kolta S, Desfougères JL, Minini P, Bidat E. Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma. Pediatrics. 2003;111(6 Pt 1)706-713.
41. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Eng J Med. 2000;343(15):1054-1063.
42. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corti-costeroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985-1997.
43. Leone FT, Fish JE, Szefler SJ, et al. Systemic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest. 2003;124(6):2329-2340.
44. Pauwels RA, Pederson S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomized double-blind trial. Lancet. 2003;361(9363):1071-1076.
45. Brogden RN, McTavish D. Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs. 1992;44(3):375-407.
46. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr. 1998;132(6):976-982.
47. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Eng J Med. 2000;343(15):1054-1063.
48. Sheffer AL, Silverman M, Woolcock AJ, Díaz PV, Lindberg B, Lindmark B. Long-term safety of once-daily budesonide in patients with early-onset mild persistent asthma: Results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. Ann Allergy Asthma Immunol. 2005;94(1):48-54.
49. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343(15):1064-1069.
50. Wolters OD. Impact of inhaled and intranasal corticosteroids on the growth of children. BioDrugs. 2000;13(5):347-357.
51. Inoue T, Doi S, Takamatsu I, Murayama N, Kameda M, Toyoshima K. Effect of long-term treatment with inhaled belcometasone dipro-pionate on growth of asthmatic children. J Asthma. 1999;36(2): 159-164.
52. Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. Paediatr Drugs. 2007;9(3):185-194.
53. Pederson S. Clinical safety of inhaled corticosteroids for asthma in children: an update of long-term trials. Drug Saf. 2006;29(7):599-612.
54. Pauwels RA, Ofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337(20):1405-1411.
55. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1392-1397.
56. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone; an analysis of asthma exacerbations. J Allergy Clin Immunol. 2001;107(5): 783-789.
57. Ni CM, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonist to inhaled steroids as first line therapy for persistent asthma in steroid-naïve adults. Cochrane Database Syst Rev. 2005;2:CD005307.
58. Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 2004;292(3):367-376.
59. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax. 2005;60(9):730-734.
60. Tal A, Simon G, Vermeulen JH, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol. 2002;34(5):342-350.
61. Pohunek P, Kuna P, Jorup C, Boeck KD. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatr Allergy Immunol. 2006;17(6):458-465.
62. van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 1996;9(8):1684-1688.
63. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997;10(11):2484-2489.
64. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler®. Respir Med. 1998;92(8):1017-1021.
65. Seberová E, Andersson A. Oxis® (formoterol given by Turbuhaler®) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med. 2000;94(6):607-611.
66. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26.
67. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003;124(1):70-74.
68. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364(9444):1505-1512.
69. Wechsler ME, Lehman E, Lazarus SC, et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173(5):519-526.
70. Bisgaard H. Effect of long-acting beta2 agonist on exacerbation rates of asthma in children. Pediatr Pulmonol. 2003;36(5):391-398.
71. Lazarus SC, Boushey HA, Fahy JV, et al; Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute. Long-acting beta2 agonist monotherapy vs continued therapy with inhaled cortico-steroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285(20):2583-2593.
72. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to long-acting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007;370:2118-2125.
73. Lofdahl CG, Reise TF, Leff JA, et al. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999;319(7202):87-90.
74. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58(3):211-216.
75. Lofdahl CG, Reise TF, Leff JA, et al. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999;319(7202):87-90.
76. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/ salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000;106(6):1088-1095.
77. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest. 2001;120(2):423-430.
78. Ringdal N, Eliraz A, Pruzinec R, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med. 2003;97(3):234-241.
79. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171(2):129-136.
80. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006;129(2):246-256.
81. Bisgaard H, Le Roux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest. 2006;130(6):1733-1743.
82. Rice-McDonald G, Bowler S, Staines G, Mitchell C. Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults. Intern Med J. 2005;35(12):693-698.
83. FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J; Canadian Asthma Exacerbation Study Group. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax. 2004;59(7):550-556.
84. Garrett J, Williams S, Wong C, Holdaway D. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child. 1998;79(1):12-17.
85. Jónasson G, Carlsen KH, Sødal A, Jonasson C, Mowinckel P. Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma. Eur Respir J. 1999;14(1):150-154.